Kymera Therapeutics, Inc.

NASDAQ (USD): Kymera Therapeutics, Inc. (KYMR)

Last Price

42.02

Today's Change

+1.20 (2.93%)

Day's Change

39.29 - 42.32

Trading Volume

345,340

Overview

Market Cap

2 Billion

Shares Outstanding

64 Million

Avg Volume

431,301

Avg Price (50 Days)

45.76

Avg Price (200 Days)

41.30

PE Ratio

-17.96

EPS

-2.34

Earnings Announcement

20-Feb-2025

Previous Close

40.82

Open

40.33

Day's Range

39.29 - 42.32

Year Range

22.35 - 53.27

Trading Volume

349,995

Price Change Highlight

1 Day Change

2.94%

5 Day Change

8.69%

1 Month Change

-8.61%

3 Month Change

-15.06%

6 Month Change

40.58%

Ytd Change

65.76%

1 Year Change

56.56%

3 Year Change

-32.18%

5 Year Change

26.34%

10 Year Change

26.34%

Max Change

26.34%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment